FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162702982> ?p ?o ?g. }

• W3162702982 abstract "HIV drug resistance (HIV-DR) is rising in sub-Saharan Africa in both ART-naive and ART-experienced patients.To estimate the level of acquired DR (ADR) and pre-treatment DR (PDR) across selected urban and rural sites in Southern Africa, in Mozambique.We conducted two cross-sectional surveys among adult HIV patients (October 2017-18) assessing ADR and PDR. In the (ADR) survey, those on NNRTI-based first-line ART for ≥6 months were recruited (three sites). In the PDR survey, those ART-naive or experienced with ≥3 months of treatment interruption prior were enrolled (eight sites).Among 1113 ADR survey participants 83% were receiving tenofovir (TDF)/lamivudine (3TC)/efavirenz (EFV). The median time on ART was 4.5 years (Maputo) and 3.2 years (Tete), 8.3% (95% CI 6.2%-10.6%, Maputo) and 15.5% (Tete) had a VL ≥ 1000 copies/mL, among whom 66% and 76.4% had NNRTI+NRTI resistance, and 52.8% and 66.7% had 3TC+TDF-DR. Among those on TDF regimens, 31.1% (Maputo) and 42.2% (Tete) were still TDF susceptible, whereas 24.4% and 11.5% had TDF+zidovudine (ZDV)-DR. Among those on ZDV regimens, 25% and 54.5% had TDF+ZDV-DR. The PDR survey included 735 participants: NNRTI-PDR was 16.8% (12.0-22.6) (Maputo) and 31.2% (26.2-36.6) (Tete), with a higher proportion (≥50%) among those previously on ART affected by PDR.In Mozambique, viral failure was driven by NNRTI and NRTI resistance, with NRTI DR affecting backbone options. NNRTI-PDR levels surpassed the WHO 10% 'alert' threshold. Replacing NNRTI first-line drugs is urgent, as is frequent viral load monitoring and resistance surveillance. Changing NRTI backbones when switching to second-line regimens may need reconsideration." @default.
• W3162702982 created "2021-05-24" @default.
• W3162702982 creator A5010325932 @default.
• W3162702982 creator A5020345166 @default.
• W3162702982 creator A5022632394 @default.
• W3162702982 creator A5023075833 @default.
• W3162702982 creator A5033108244 @default.
• W3162702982 creator A5037331636 @default.
• W3162702982 creator A5058069445 @default.
• W3162702982 creator A5066321735 @default.
• W3162702982 creator A5068858270 @default.
• W3162702982 creator A5068932624 @default.
• W3162702982 creator A5072891689 @default.
• W3162702982 creator A5085080095 @default.
• W3162702982 creator A5086905563 @default.
• W3162702982 creator A5087963286 @default.
• W3162702982 date "2021-04-08" @default.
• W3162702982 modified "2023-10-14" @default.
• W3162702982 title "High level of HIV drug resistance informs dolutegravir roll-out and optimized NRTI backbone strategy in Mozambique" @default.
• W3162702982 cites W1987208122 @default.
• W3162702982 cites W2043256741 @default.
• W3162702982 cites W2090564884 @default.
• W3162702982 cites W2093274439 @default.
• W3162702982 cites W2239032355 @default.
• W3162702982 cites W2395838540 @default.
• W3162702982 cites W2470418554 @default.
• W3162702982 cites W2516621031 @default.
• W3162702982 cites W2744753912 @default.
• W3162702982 cites W2752427976 @default.
• W3162702982 cites W2773554166 @default.
• W3162702982 cites W2791035016 @default.
• W3162702982 cites W2800677865 @default.
• W3162702982 cites W2802989165 @default.
• W3162702982 cites W2809119885 @default.
• W3162702982 cites W2936279454 @default.
• W3162702982 cites W2946852828 @default.
• W3162702982 cites W2953075798 @default.
• W3162702982 cites W3108956197 @default.
• W3162702982 doi "https://doi.org/10.1093/jacamr/dlab050" @default.
• W3162702982 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8209982" @default.
• W3162702982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34223118" @default.
• W3162702982 hasPublicationYear "2021" @default.
• W3162702982 type Work @default.
• W3162702982 sameAs 3162702982 @default.
• W3162702982 citedByCount "4" @default.
• W3162702982 countsByYear W31627029822021 @default.
• W3162702982 countsByYear W31627029822022 @default.
• W3162702982 countsByYear W31627029822023 @default.
• W3162702982 crossrefType "journal-article" @default.
• W3162702982 hasAuthorship W3162702982A5010325932 @default.
• W3162702982 hasAuthorship W3162702982A5020345166 @default.
• W3162702982 hasAuthorship W3162702982A5022632394 @default.
• W3162702982 hasAuthorship W3162702982A5023075833 @default.
• W3162702982 hasAuthorship W3162702982A5033108244 @default.
• W3162702982 hasAuthorship W3162702982A5037331636 @default.
• W3162702982 hasAuthorship W3162702982A5058069445 @default.
• W3162702982 hasAuthorship W3162702982A5066321735 @default.
• W3162702982 hasAuthorship W3162702982A5068858270 @default.
• W3162702982 hasAuthorship W3162702982A5068932624 @default.
• W3162702982 hasAuthorship W3162702982A5072891689 @default.
• W3162702982 hasAuthorship W3162702982A5085080095 @default.
• W3162702982 hasAuthorship W3162702982A5086905563 @default.
• W3162702982 hasAuthorship W3162702982A5087963286 @default.
• W3162702982 hasBestOaLocation W31627029821 @default.
• W3162702982 hasConcept C114851261 @default.
• W3162702982 hasConcept C126322002 @default.
• W3162702982 hasConcept C142462285 @default.
• W3162702982 hasConcept C159047783 @default.
• W3162702982 hasConcept C2522874641 @default.
• W3162702982 hasConcept C2777869810 @default.
• W3162702982 hasConcept C2778451633 @default.
• W3162702982 hasConcept C2779502633 @default.
• W3162702982 hasConcept C2780216070 @default.
• W3162702982 hasConcept C2780593183 @default.
• W3162702982 hasConcept C2780727368 @default.
• W3162702982 hasConcept C2781432083 @default.
• W3162702982 hasConcept C2993143319 @default.
• W3162702982 hasConcept C3013748606 @default.
• W3162702982 hasConcept C71924100 @default.
• W3162702982 hasConcept C86803240 @default.
• W3162702982 hasConcept C89423630 @default.
• W3162702982 hasConceptScore W3162702982C114851261 @default.
• W3162702982 hasConceptScore W3162702982C126322002 @default.
• W3162702982 hasConceptScore W3162702982C142462285 @default.
• W3162702982 hasConceptScore W3162702982C159047783 @default.
• W3162702982 hasConceptScore W3162702982C2522874641 @default.
• W3162702982 hasConceptScore W3162702982C2777869810 @default.
• W3162702982 hasConceptScore W3162702982C2778451633 @default.
• W3162702982 hasConceptScore W3162702982C2779502633 @default.
• W3162702982 hasConceptScore W3162702982C2780216070 @default.
• W3162702982 hasConceptScore W3162702982C2780593183 @default.
• W3162702982 hasConceptScore W3162702982C2780727368 @default.
• W3162702982 hasConceptScore W3162702982C2781432083 @default.
• W3162702982 hasConceptScore W3162702982C2993143319 @default.
• W3162702982 hasConceptScore W3162702982C3013748606 @default.
• W3162702982 hasConceptScore W3162702982C71924100 @default.
• W3162702982 hasConceptScore W3162702982C86803240 @default.
• W3162702982 hasConceptScore W3162702982C89423630 @default.
• W3162702982 hasFunder F4320307843 @default.
• W3162702982 hasIssue "2" @default.

• next